Cochrane Review on primaquine to prevent malaria transmission

Researchers from the Cochrane Infectious Diseases Group, hosted at LSTM, conducted an independent review of the effects of adding a single dose of primaquine (PQ) to malaria treatment to prevent the transmission of the disease.

Mosquitoes become infected with Plasmodium falciparum when they ingest gametocyte-stage parasites from an infected person's blood. PQ is an antimalarial drug that does not cure illness, but is known to kill the gametocyte stage of the P falciparum parasite, thus potentially limiting transmission to further humans. PQ is known to have potentially serious side effects for those who have the glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency, which is common in many malaria endemic regions.

In 2012 the World Health Organization (WHO) revised its recommendation for a single dose of PQ alongside treatment for P. falciparum malaria from 0.75 mg/kg down to 0.25mg/kg due to concerns about safety. The three authors looked at a total of 18 trials to examine the evidence of benefits and harms of using PQ in this way by evaluating whether PQ will reduce or the potential that it will reduce transmission based on infectious stages (gametocytes) in the blood. This fresh analysis grouped the studies by dose, to evaluate the effects of the low dose currently recommended by the WHO.

None of the included studies tested whether PQ added to reduced the community transmission intensity of malaria. Two studies showed that PQ at doses of 0.75 mg/kg reduced the number of mosquitoes infected after biting humans. PQ does reduce the proportion of people with gametocyte stages, the numbers of gametocytes and the duration of infectiousness (the period that gametocytes are detected in the blood) at doses of 0.4 mg/kg or above, but two trials at lower doses showed no effect.

Patricia Graves, from James Cook University in Cairns, said: "Evidence shows that at PQ doses of 0.4 mg/kg and above there is reduction in infectiousness of individuals. Whether this translates into an effect at community level in reducing transmission is not clear. Given the lack of safety data in those with G6PD deficiency, the data do not reveal whether the revised dosing recommendation will have a positive impact on health."

More information: onlinelibrary.wiley.com/doi/10… 008152.pub3/abstract

add to favorites email to friend print save as pdf

Related Stories

Low-dose treatment may block malaria transmission

Nov 14, 2013

Lower doses of the antimalarial drug primaquine are as effective as higher doses in reducing malaria transmission, according to a study published today in Lancet Infectious Diseases by London School of Hygiene & Tropical Medici ...

Recommended for you

Ebola reveals shortcomings of African solidarity

2 hours ago

As Africa's leaders meet in Ethiopia to discuss the Ebola crisis, expectations of firm action will be tempered by criticism over the continent's poor record in the early stages of the epidemic.

Second bird flu case confirmed in Canada

18 hours ago

The husband of a Canadian who was diagnosed earlier this week with bird flu after returning from a trip to China has also tested positive for the virus, health officials said Friday.

What exactly is coronavirus?

Jan 30, 2015

The conflicts in Syria and Iraq are straining public health systems and public health efforts meant to prevent and detect the spread of infectious diseases. This is generating a "perfect storm" of conditions for outbreaks. Among the infections raising concern is Middle East Respiratory Syndrome, caused by a type of coronavirus, which emerged in 2012. ...

Scientists find Ebola virus is mutating

Jan 30, 2015

(Medical Xpress)—Researchers working at Institut Pasteur in France have found that the Ebola virus is mutating "a lot" causing concern in the African countries where the virus has killed over eight thous ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.